Acne scars no longer have to be a permanent reminder—discover how cutting-edge treatments like exosomes and fractional CO2 ...

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...

A Phase I clinical trial has demonstrated the long-term safety of neural stem cell transplantation for chronic spinal cord ...

Injuries of the knee resulting in damage to ... with HA are essential for processes like cell migration and tissue repair, ...

Humacyte (NASDAQ:HUMA) shares climbed ~57% in the premarket on Friday after the bioengineered tissue maker announced the FDA ...

Silver Spring, Md Thursday, December 26, 2024, 11:00 Hrs [IST] ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod ...

A Durham company secured federal approval for its bioengineered tissue, which could become a revolutionary treatment for ...

SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

Nanofibers as scaffolds in spinal cord repair Spinal cord injury is accompanied by tissue damage and the formation of physical and biochemical barriers that prevent axons from regenerating.

The U.S. Food and Drug Administration approved Symvess, the first acellular tissue engineered vessel indicated for use in ...